Another month, another gliflozin filing in Japan
This article was originally published in Scrip
Approval submissions for Japan's next class of diabetes drugs, the "gliflozin" sodium-glucose co-transporter 2 (SGLT2) inhibitors, continue to come thick and fast, with Sanofi and Kowa the latest to enter the highly competitive fray with tofogliflozin (CSG452).
You may also be interested in...
Japanese ophthalmic specialist picks up young private US firm and gains a small but broad set of marketed products.
Cancer deals involving Junshi/Wigen, Allist/Octimet, Yufan/Abound, Takeda/Presage, Daiichi Sankyo/AnHeart, LegoChem/Harbour Biomed, plus a stem cell partnership and a lysosomal storage disorder agreement.
Japan coordinates initiative to improve regional early-stage development of novel cancer therapies, which will work both with the industry and independently to improve access.